<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041586</url>
  </required_header>
  <id_info>
    <org_study_id>VAPOR-US</org_study_id>
    <nct_id>NCT01041586</nct_id>
  </id_info>
  <brief_title>Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction</brief_title>
  <acronym>BTVA</acronym>
  <official_title>US Pilot Safety and Feasibility Study of Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients With Heterogeneous Emphysema With Upper Lobe Predominance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uptake Medical Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uptake Medical Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous
      upper lobe emphysema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects meeting the eligibility criteria and who provide written informed consent will
      be enrolled. Immediately prior to BTVA treatment, an initial bronchoscopy will be performed
      to evaluate the baseline condition of the airways and to confirm anatomy of the lung segments
      targeted for BTVA treatment. Up to 3 segments in either the right or left upper lobe will be
      treated with a vapor dose of 10 calories per gram of lung tissue (10 cal/g). Targeted lobe
      for treatment will be based on lobar disease severity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of adverse events (serious and non-serious) secondary to the BTVA treatment procedure from initiation of treatment through completion of the six-month follow-up period</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic evidence of lung volume reduction (assessed by study site radiologist) and CT scan (assessed by blinded radiologist at CT core lab)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>BTVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BTVA System</intervention_name>
    <description>Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction</description>
    <arm_group_label>BTVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: &gt; 40 and ≤ 75 years old

          2. Diagnosis of heterogeneous emphysema with upper lobe predominance

          3. FEV1 &lt; 45% predicted

          4. TLC &gt; 100% predicted

          5. RV &gt; 150% predicted

          6. 6-minute walk test &gt; 140 meters

          7. mMRC ≥ 2 (mMRC)

          8. Non-smoking for 3 months

          9. Optimized medical management and completed pulmonary rehabilitation

        Exclusion Criteria:

          1. Known α-1-antitrypsin deficiency

          2. BMI &lt; 15 kg/m2 or &gt; 35 kg / m2

          3. History of pneumothorax within previous 18 months

          4. History of heart and / or lung transplant, lung volume reduction surgery (LVRS),
             median sternotomy, bullectomy, and/or lobectomy

          5. Respiratory infections or recurring COPD exacerbations &gt; 3 hospitalizations in past 12
             months or active infection

          6. History of the (EF) ≤ 40%; Stroke; Unstable Myocardial Ischemia; FEV1 &lt; 15% predicted;
             DLCO &lt; 20% predicted; of pulmonary hypertension; indwelling pacemaker or implantable
             cardiac defibrillator (ICD); pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John C. Lincoln Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emphysema</keyword>
  <keyword>COPD</keyword>
  <keyword>Lung Volume Reduction</keyword>
  <keyword>BTVA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

